The overexpression of YTHDF1 has been widely regarded as a diagnostic and prognostic biomarker in various tumors, particularly in gastric colorectal cancer, prostate cancer, cervical cancer, hepatocellular carcinoma, breast cancer, and non-small-cell lung cancer. Here, YTHDF1 is linked to prostate cancer.